© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
October 15, 2017
While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.